New ALS drug safety trial launches for Long-Term study

NCT ID NCT07571174

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests the long-term safety of a drug called LY4256984, given via spinal injection, in people with ALS. It includes 32 participants who completed an earlier study and will be followed for about 96 weeks. The main goal is to see how many people have serious side effects related to the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4256984 (a drug given via spinal injection)
What this could lead to: If successful, this could show that LY4256984 is safe enough to continue testing as a potential treatment to slow ALS progression.
What could go wrong: This is a very early (Phase 1) study with only 32 participants. It focuses on safety, not effectiveness, so it may not lead to a working treatment. Spinal injections carry risks like back pain or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis sporadic amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Hospital Universitari de Bellvitge
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, 08907, Spain
Hospital Universitari i Politecnic La Fe
NOT_YET_RECRUITING

Valencia, 46026, Spain
McGill University Health Centre
RECRUITING

Montreal, H4A 3J1, Canada
Sunnybrook Research Institute
NOT_YET_RECRUITING

Toronto, M4N 3M5, Canada
UZ Leuven
NOT_YET_RECRUITING

Leuven, 3000, Belgium
Universitaetsklinikum Ulm
NOT_YET_RECRUITING

Ulm, 89081, Germany
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITING

Utrecht, 3584 CX, Netherlands
University Hospital - London Health Sciences Centre
NOT_YET_RECRUITING

London, N6A 5A5, Canada
Universitätsklinikum Schleswig-Holstein
NOT_YET_RECRUITING

Lübeck, 23538, Germany
Universitätsmedizin Rostock
NOT_YET_RECRUITING

Rostock, 18147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.